EXEL
Price
$37.21
Change
+$0.43 (+1.17%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
10.05B
19 days until earnings call
MRSN
Price
$0.36
Change
-$0.03 (-7.69%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
45.15M
18 days until earnings call
Ad is loading...

EXEL vs MRSN

Header iconEXEL vs MRSN Comparison
Open Charts EXEL vs MRSNBanner chart's image
Exelixis
Price$37.21
Change+$0.43 (+1.17%)
Volume$37K
Capitalization10.05B
Mersana Therapeutics
Price$0.36
Change-$0.03 (-7.69%)
Volume$39.91K
Capitalization45.15M
EXEL vs MRSN Comparison Chart
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. MRSN commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a StrongBuy and MRSN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (EXEL: $36.74 vs. MRSN: $0.38)
Brand notoriety: EXEL: Notable vs. MRSN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 96% vs. MRSN: 119%
Market capitalization -- EXEL: $10.05B vs. MRSN: $45.15M
EXEL [@Biotechnology] is valued at $10.05B. MRSN’s [@Biotechnology] market capitalization is $45.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 1 FA rating(s) are green whileMRSN’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 1 green, 4 red.
  • MRSN’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than MRSN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 6 TA indicator(s) are bullish while MRSN’s TA Score has 6 bullish TA indicator(s).

  • EXEL’s TA Score: 6 bullish, 4 bearish.
  • MRSN’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, MRSN is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а +1.63% price change this week, while MRSN (@Biotechnology) price change was +14.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

EXEL is expected to report earnings on Aug 12, 2025.

MRSN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($10.1B) has a higher market cap than MRSN($45.2M). EXEL YTD gains are higher at: 10.330 vs. MRSN (-73.077). EXEL has higher annual earnings (EBITDA): 719M vs. MRSN (-63.27M). EXEL has more cash in the bank: 1.11B vs. MRSN (135M). MRSN has less debt than EXEL: MRSN (28.6M) vs EXEL (191M). EXEL has higher revenues than MRSN: EXEL (2.17B) vs MRSN (40.5M).
EXELMRSNEXEL / MRSN
Capitalization10.1B45.2M22,345%
EBITDA719M-63.27M-1,136%
Gain YTD10.330-73.077-14%
P/E Ratio20.88N/A-
Revenue2.17B40.5M5,356%
Total Cash1.11B135M823%
Total Debt191M28.6M668%
FUNDAMENTALS RATINGS
EXEL vs MRSN: Fundamental Ratings
EXEL
MRSN
OUTLOOK RATING
1..100
1220
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
23100
SMR RATING
1..100
4199
PRICE GROWTH RATING
1..100
4093
P/E GROWTH RATING
1..100
89100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (75) in the Biotechnology industry is in the same range as MRSN (88). This means that EXEL’s stock grew similarly to MRSN’s over the last 12 months.

EXEL's Profit vs Risk Rating (23) in the Biotechnology industry is significantly better than the same rating for MRSN (100). This means that EXEL’s stock grew significantly faster than MRSN’s over the last 12 months.

EXEL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for MRSN (99). This means that EXEL’s stock grew somewhat faster than MRSN’s over the last 12 months.

EXEL's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for MRSN (93). This means that EXEL’s stock grew somewhat faster than MRSN’s over the last 12 months.

EXEL's P/E Growth Rating (89) in the Biotechnology industry is in the same range as MRSN (100). This means that EXEL’s stock grew similarly to MRSN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELMRSN
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
54%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 21 days ago
62%
Bearish Trend 21 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
54%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NEXT7.360.16
+2.22%
NextDecade Corp
CLRO0.500.01
+2.02%
ClearOne
FLR34.440.56
+1.65%
Fluor Corp
CTAS207.691.85
+0.90%
Cintas Corp
FRBA13.70-0.43
-3.04%
First Bank

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+0.71%
SRPT - EXEL
36%
Loosely correlated
+0.30%
ALNY - EXEL
34%
Loosely correlated
+2.20%
TECH - EXEL
33%
Poorly correlated
+2.20%
MRSN - EXEL
32%
Poorly correlated
+2.39%
ORMP - EXEL
32%
Poorly correlated
+0.66%
More